Signal Transduction
Differential activities and mechanisms of the four R-spondins in potentiating Wnt/β-catenin signalingDistinct activities of RSPO1–4

https://doi.org/10.1074/jbc.RA118.002743Get rights and content
Under a Creative Commons license
open access

The four R-spondins (RSPO1–4) strongly potentiate Wnt signaling and play critical roles in normal development, adult stem cell survival, and cancer development and aggressiveness. All four RSPOs have been suggested to potentiate Wnt signaling by binding to three related receptors, i.e. leucine-rich repeat–containing, G protein–coupled receptors 4, 5, and 6 (LGR4/5/6), and then inducing the clearance of two E3 ubiquitin ligases (RNF43 and ZNRF3) that otherwise would ubiquitinate Wnt receptors for degradation. Here, we show that RSPO1–4 have differential dependence on LGRs in potentiating Wnt/β-catenin signaling and that RSPO2 can enhance this pathway without any LGR. LGR4 knockout (LGR4KO) in HEK293 cells completely abrogated the Wnt/β-catenin signaling response to RSPO1 and RSPO4 and strongly impaired the response to RSPO3. RSPO2, however, retained robust activity albeit with decreased potency. Complete rescue of RSPO1–4 activity in LGR4KO cells required the seven-transmembrane domain of LGR4. Furthermore, an RSPO2 mutant with normal binding affinity to ZNRF3 but no or little binding to LGR4 or LGR5 still potentiated Wnt/β-catenin signaling in vitro, supported the growth of intestinal organoids ex vivo, and stimulated intestinal crypt growth in vivo. Mechanistically, RSPO2 could increase Wnt receptor levels in the absence of any LGR without affecting ZNRF3 endocytosis and stability. These findings suggest that RSPO1–4 use distinct mechanisms in regulating Wnt and other signaling pathways, which have important implications for understanding the pleiotropic functions of RSPOs and LGRs in both normal and cancer development.

cell signaling
stem cells
7-helix receptor
Wnt signaling
beta-catenin (β-catenin)
LGR4
LGR5
organoids
R-spondin

Cited by (0)

This work was supported in part by Cancer Prevention and Research Institute of Texas Grants RP160235 and RP170245 and the Janice D. Gordon endowment for bowel cancer research (to Q. J. L). Q. J. L. is a cofounder of Wntrix, and J. C. is a full-time employee of Wntrix.

This article contains Figs. S1–S6.